Gratifyingly, OI reduced IL-1β release in PBMCs from CAPS patients treated with LPS (77), demonstrating that itaconate-based therapeutics could be effective against NLRP3-associated diseases in humans. This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.